Cerebrospinal fluid biomarkers of neurodegeneration in narcolepsy type 1.
To measure the levels of five neurodegenerative biomarkers in the cerebrospinal fluid (CSF) of patients with narcolepsy type 1 (NT1) with variable disease duration. Following a standardized protocol of CSF collection and storage, we measured CSF total-and phosphorylated-tau, amyloid-beta 1-40 and 1-42, and neurofilament light chain proteins in 30 non-neurological controls and 36 subjects with NT1, including 14 patients with recent disease onset (i.e. ≤ 12 months, short disease duration group). CSF levels of all biomarkers were similar in NT1 subjects and controls. The comparison between NT1 with short and long disease duration only revealed slightly higher levels of CSF amyloid-beta 40 in the former group (median 9549.5, IQR 7064.2-11525.0 vs. 6870.0, IQR 5133.7-9951.2, p=0.043). CSF storage time did not influence the levels of the tested biomarkers. The measurement of CSF total-tau, phosphorylated-tau, amyloid-beta 40 and 42, and neurofilament light chain proteins is not informative in NT1.